Skip to Main Content

Paper Details

Risk Assessment of Kidney Disease Progression and Efficacy of SGLT2 Inhibition in Patients With Type 2 Diabetes.
Diabetes Care
2
2023
Chronic Kidney Disease, Dapagliflozin, Kidney Disease, Patients, SGLT2, T2D, Type 2 Diabetes, albumin, atherosclerotic cardiovascular disease, creatinine, dapagliflozin, end-stage kidney disease, glucose, glycated hemoglobin, heart failure, hemoglobin, kidney disease, patients, sodium, type 2 diabetes
Author NameAffiliation
Jamie P DwyerUniversity of Utah Health
Benjamin M SciricaBrigham and Women's Hospital, Harvard Medical School
Deepak L BhattIcahn School of Medicine at Mount Sinai Health System
Eugene BraunwaldBrigham and Women's Hospital, Harvard Medical School
David A MorrowBrigham and Women's Hospital, Harvard Medical School
David A MorrowBrigham and Women's Hospital, Harvard Medical School
Marc S SabatineBrigham and Women's Hospital, Harvard Medical School
Marc S SabatineBrigham and Women's Hospital, Harvard Medical School
  • 1 - 8

Datasets

Release 1.2